Drug Profile
Research programme: cannabinoid receptor agonists - Cara
Alternative Names: CR08; CR701; CR859Latest Information Update: 23 Mar 2021
Price :
$50
*
At a glance
- Originator Cara Therapeutics
- Class
- Mechanism of Action Cannabinoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory pain; Neuropathic pain
Most Recent Events
- 31 Dec 2020 Cara Therapeutics has patent protection for cannabinoid receptor agonists in USA, prior to December 20202
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammatory-pain in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in USA (PO)